|
Daily Medical Update
Upper airway cough syndrome
Wednesday, April 08, 2026
|
🔬 Practice‑Changing Findings
Evidence from RCTs and meta‑analyses published in the last 12 months.
|
Pneumologie (Stuttgart, Germany) (2025) - Practice Guideline
Key Findings
- The guideline identifies UACS as one of the key chronic cough etiologies and recommends symptom-based evaluation to reduce unnecessary broad diagnostic testing.
- Consensus recommendations support empiric UACS treatment when the clinical picture fits, while shared decision-making is advised when evidence is limited to improve alignment with patient goals.
📋 Practice Implication: Use a structured cough algorithm first: screen for red flags, assess for upper-airway features early, and reserve broader testing for atypical or refractory presentations.
|
Pediatric pulmonology (2025) - Multicenter Cohort Study
Key Findings
- UACS accounted for 48 of 363 pediatric referrals (13%), while asthma and asthma-like conditions accounted for 36% and no etiology was found in 20%.
- Asthma diagnoses increased 3.5-fold in schoolchildren, whereas RTI/PBB diagnoses increased threefold in preschoolers, supporting age-specific differentiation when UACS is suspected.
- Nasal corticosteroids were prescribed for 83% of children diagnosed with UACS.
📋 Practice Implication: In children with prolonged cough, keep UACS in the differential but interpret upper-airway symptoms in an age-specific framework so asthma and infectious causes are not overcalled.
|
Journal of thoracic disease (2025) - Multicenter Retrospective Study
Key Findings
- Early responders were more often diagnosed with UACS than non-early responders (65.7% vs 49.2%, P=0.006).
- Higher baseline cough severity increased the odds of early response (OR 1.44; 95% CI 1.06-1.97; P=0.02).
- A UACS diagnosis independently increased the odds of early response (OR 1.76; 95% CI 1.02-3.02; P=0.04).
📋 Practice Implication: When the history strongly suggests UACS, an early empiric treatment trial with close 2- to 4-week reassessment is reasonable because improvement may occur faster than with other chronic cough etiologies.
|
ERJ Open Research (2023) - Randomized Double-Blind Placebo-Controlled Trial
Key Findings
- After 2 weeks, LCQ scores improved in both groups, but the change did not differ between bepotastine and placebo (3.45 +/- 2.10 vs 3.04 +/- 2.94; P=0.576).
- Secondary outcomes, including cough severity VAS and throat VAS, were comparable between groups, suggesting no additional cough reduction with bepotastine.
- The trial concluded that nonsedating H1-antihistamine therapy did not improve cough outcomes even in patients with persistent cough and allergic rhinitis.
📋 Practice Implication: Do not assume newer nonsedating H1 blockers will control UACS-related cough; if antihistamine therapy is chosen, expectations should be modest and alternative drivers should be reassessed quickly.
|
Advances in respiratory medicine (2026) - Retrospective Cohort Study
Key Findings
- UACS was diagnosed more often in men than women (75% vs 53%, P=0.002), and obstructive sleep apnea was also more common in men (21% vs 6%, P=0.001).
- Cough severity improved in both groups, with median VAS falling from 55 to 40 mm in women and from 69 to 39 mm in men.
- Median VAS reduction was greater in men than women (32 mm vs 17.5 mm, P=0.006).
📋 Practice Implication: Account for sex-linked presentation patterns during follow-up: men with UACS may warrant broader comorbidity screening, while slower symptomatic improvement in women may justify earlier reconsideration of overlapping mechanisms.
|
|
Recent UACS literature remains dominated by diagnostic and phenotyping studies rather than high-volume interventional trials. Newer data suggest UACS is a common, often early-responsive cause of chronic cough, with age- and sex-linked variation in diagnosis and treatment response, while the best placebo-controlled trial in this set found no cough benefit from the nonsedating H1-antihistamine bepotastine. Current guideline direction continues to favor structured symptom-based evaluation and targeted empiric therapy rather than reflex escalation to broad testing.
|
|